Summary Signal transduction pathways activated by injury play a central role in coordinating the cellular responses that determine whether a cell survives or dies. GADD153 expression increases markedly in response to some types of cellular injury and the product of this gene causes cell cycle arrest. Using induction of GADD153 as a model, we have investigated the activation of the cellular injury response after treatment with taxol and cisplatin (cDDP). Activation of the GADD153 promoter coupled to the luciferase gene and transfected into human ovarian carcinoma 2008 cells correlated well with the increase in endogenous GADD153 mRNA after treatment with taxol but not after treatment with cDDP. Following treatment with cDDP, the increase in endogenous GADD153 mRNA was 10-fold greater than the increase in GADDS53 promoter activity. Likewise, at equitoxic levels of exposure (IC80), cDDP produced a 5-fold greater increase in endogenous GADD153 mRNA than taxol. The tyrosine kinase inhibitor tyrphostin B46 had no significant effect on the ability of taxol to activate the GADDJ53 promoter, but inhibited activation of the GADD153 promoter by cDDP in a concentration-dependent manner. Tyrphostin B46 synergistically enhanced the cytotoxicity of cisplatin; however, the same exposure had no significant effect on the cytotoxicity of taxol. We conclude that (1) taxol and cDDP activate GADD153 promoter activity through different mechanisms; (2) the signal transduction pathway mediating induction by cDDP involves a tyrosine kinase inhibitable by tyrphostin B46; and (3) that inhibition of this signal transduction pathway by tyrphostin synergistically enhances cDDP toxicity.
Treatment of cells with chemotherapeutic agents results in the induction of a number of 'damage response' genes. In bacteria, rec A plays a central role in activating the SOS damage response pathway (Walker, 1985) . In yeast, ongoing work has resulted in the discovery of a large number of genes that are involved in the control of cell cycle arrest following genotoxic injury, and in the detection and repair of DNA adducts (Weinert and Hartwell, 1988; Rowley et al., 1992) . In mammalian cells, the responses to cellular injury and the signal transduction pathways that control these responses are less well understood. It is clear, however, that a large number of genes are transcriptionally activated following cell cycle arrest produced by growth factor deficiency or DNA damage (reviewed in Holbrook and Fornace, 1991) .
Most of the transcripts identified so far that are increased during the cellular injury response are also inducible by 12-0-tetradecanoyl phorbol-13-acetate (TPA) , suggesting the participation of a phorbol ester response element. GADD153 is one of the cellular injury response genes that is not transcriptionally activated by TPA (Fornace et al., 1989) . GADD153 was originally cloned by hybridisation subtraction of mRNA from UV-treated CHO cells (Fornace et al., 1988) . It is one of a family of genes that is coordinately regulated by agents that induce cellular injury through growth arrest or DNA damage (Fornace et al., 1989) . GADD153 is highly conserved in mammalian species; the hamster cDNA shares 78% nucleotide sequence identity with the human cDNA (Park et al., 1992) and> 85% with the mouse cDNA homologue (Ron and Habener, 1992) . Although the function of GADD153 in the cellular injury response is unknown, it may be a modulator of the transcription factors C/EBP and LAP. Ron and Habener (1992) cloned CHOP-10, the mouse homologue of GADD153, by identifying proteins that could dimerise with C/EBP or LAP but could not bind to the cytokine-responsive enhancer element APRE (acute-phase responsive element). They found that CHOP-10 was localised to the nucleus and co-immumoprecipitated with LAP. They also found that overexpression of CHOP-10 inhibited the activation of an APRE-driven luciferase construct.
Although GADD153 is not induced by TPA, it is induced by a variety of agents that cause cellular injury. These include UV light, serum starvation, media depletion (Fornace et al., 1989) , cysteine conjugates, dithiothreitol (Chen et al., 1992) , terminal differentiation (in some cases) , hypoxia (Price and Calderwood, 1992) and various chemotherapeutic drugs and alkylating agents Holbrook, 1992, 1994) . We have shown that treatment with the chemotherapeutic agent cDDP increases GADD153 mRNA levels in 2008 ovarian carcinoma cells both when grown in vitro and as xenografts in nude mice (Gately et al., 1994) . However, neither the signal transduction pathways nor the biochemical mechanisms that are responsible for the induction of GADD153 by cDDP have been identified. Barlett et al. (1992) postulated that the induction is dependent on an increase in intracellular calcium, but the specific transcription factors involved remain to be elucidated.
Recently it was reported (Aman et al., 1992; Crozat et al., 1993) that GADD153 is involved in the oncogenesis of human myxoid liposarcomas. It was demonstrated that the characteristic chromosomal translocation found in this tumour type creates a fusion protein of GADD153 and a previously unreported RNA-binding protein (named TLS for translocated in liposarcoma; Crozat et al., 1993) . This fusion protein contains the DNA-binding and leucine-zipper domains of the GADD153 protein fused to a domain in TLS that has a glycine-rich region similar to that of the transcription factor Spl. It was hypothesised that this translocation changes the effect of GADD153/CHOP-10 from a transcriptional suppressor to an oncogenic transcriptional activator.
We have studied the activation of the GADD153 promoter by two chemotherapeutic agents that induce cellular injury through different mechanisms. In these studies we used human ovarian carcinoma cells and two drugs that are important in the treatment of this disease. cDDP is thought to damage cells by forming adducts in DNA (Pinto and Lippard, 1985) , whereas taxol binds to tubulin and alters its Correspondence: DP Gately polymerisation dynamics in a manner that prevents functioning of the mitotic spindle (Rowinsky et al., 1993 Luciferase assay pGADD-LUC, a GADDJ53 promoter-driven luciferase reporter construct was created by ligating the ClaI/HindIII fragment of p9000 (a gift from Dr NJ Holbrook, NIA, NIH, Baltimore, MD, USA), containing the hamster GADD153 promoter into the AccI/HindIII site of pB-LUC (Luethy et al., 1990) . pB-LUC contains the firefly luciferase gene ligated into the BamHI site of pBluescript KS-(a gift from Dr L Quattrochi).
The cells were transfected with the pGADD-LUC construct by a modification of the method described by Rose et al. (1991) . Cells were plated at 3 x I05 cells per 35 mm dish, and then 18 h later they were incubated at 37°C with 5 jig of plasmid DNA and 30 ,l of liposomes in I ml of RPMI-1640. After 3 h the lipids were removed and the cells were treated with cDDP for 1 h or taxol for 24 h. Six hours after the end of cDDP exposure, or after the 24 h taxol exposure, the cells were lysed in 500 gl of lysis buffer (25 mM glycylglycine, pH 7.8, 15 mM magnesium sulphate, 4 mM EGTA, 1% Triton X-100, 1 mm dithiothreitol). Luciferase activity was measured by a modification of the method described by Brasier et al. (1989) . Cell lysate (50 gl) was added to 200 tll of reaction buffer (lysis buffer with 15 mm potassium phosphate, pH 7.8, and 2 mM ATP added). Light emission was measured after injection of 100 pl of 1 mM luciferin into the lysate/reaction mixture using a MonoLight 2001 (Analytical Luminescence).
Northern blotting Total cellular RNA was extracted and Northern blots prepared using MagnaGraph nylon membranes (MSI, Westboro, MA, USA) by standard techniques (Davis et al., 1986) . The extent of hybridisation was quantified by the Molecular Imager System (Bio-Rad, Hercules, CA, USA). The human GADD153 probe was a gift of Dr NJ Holbrook. Lane loading differences were corrected for by comparison to the same blot hybridised with a P-actin probe.
Colony forming assays and median effect analysis Three hundred cells were plated per dish and allowed to attach overnight. The cells were treated with tyrphostin B46 or DMSO for 1 h followed by a 1 h concurrent exposure with DDP, or a concurrent 24 h exposure to taxol. After DDP Cisplatin and taxol-induced GADD153 expression D P Gately et al 19 exposure, tyrphostin B46 or DMSO was added back to the media for a total exposure of 24 h. After drug exposure, the media was replaced and at 10 days after treatment, colonies of 50 cells or more were counted. Median effect analysis was carried out as described by Chou and Talalay (1986) .
Results
Effect of taxol and cDDP on activation of the GADD 153 promoter and endogenous GADD 153 mRNA Human ovarian 2008 cells were transiently transfected with pGADD-LUC, which contains 786 basepairs of the hamster GADD153 promoter coupled to the luciferase reporter gene. They were then exposed to taxol for 24 h over a concentration range corresponding to 1-10 times the IC50, and luciferase activity was measured 24 h after the start of drug exposure, which previous work had shown to be the time of peak luciferase activity (data not shown). Figure la shows the change in luciferase activity expressed relative to the level in untreated control cells; and indicates that taxol activated the GADD153 promoter in a concentration-dependent manner. Figure 1 b shows the effect of the same taxol exposure on the change in endogenous GADD153 mRNA levels in nontransfected cells determined by Northern blot analysis of RNA harvested 24 h after the start of drug exposure. Taxol increased the level of endogenous GADD153 mRNA in a dose-dependent manner that corresponded well with its effect on GADD153 promoter activation. Similar experiments were conducted with cDDP in which 2008 cells were transiently transfected with pGADD-LUC and exposed to cDDP for 1 h. Maximal levels of luciferase activity were found to occur at 6 h after the end of a 1 h drug exposure (data not shown). Figure 2a shows that over an equitoxic concentration range cDDP caused substantially less activation of the GADD153 promoter, as reflected by luciferase activity, than did taxol. However, Figure 2b shows that cDDP produced up to a 40-fold increase in endogenous GADD153 mRNA level after drug treatment (note the difference in the ordinate scale in a and b). Thus, in contrast to what was observed with taxol, in the case of cDDP there was a much smaller effect on promter activity than on endogenous GADD153 level. Figure 3 shows that there is a good correlation between the fold change in endogenous mRNA and the fold activation of the GADDJ53 promoter for cDDP (r = 0.94) and taxol (r = 0.96). However the slope of the least mean squares line was 1.1 for taxol as opposed to 29.5 for cDDP. Thus, for a given degree of activation of the transfected promoter, the effect on endogenous GADDJ53 mRNA level was 27-fold greater for cDDP than for taxol. This indicates that the mechanisms by which the two drugs produce these changes differ in at least some components. Figure 4 shows an analysis of the correlation between the degree of cytotoxicity produced by the drug exposure and the change in endogenous GADDJ53 mRNA. For both agents there was an excellent correlation (cDDP, r = 0.98; taxol, r = 0.97). Relative luciferase activity Figure 3 Correlation between drug effect on relative endogenous m7 GADD153 mRNA levels and relative luciferase activity. For known doses of drug, endogenous mRNA levels were plotted relative to luciferase activity. Linear regression curves (linear least squares method) were plotted using DeltaGraph for the Macintosh software (DeltaPoint, Monterev. CA, USA). *. Taxol: *.
cDDP. Cisplatin and taxol-induced GADD153 expressioni D P Gately et al re no significant effect on the basal activity of the GADD153 promoter. However, tyrphostin B46 significantly inhibited the cDDP-induced activation of the GADD153 promoter in a dose-dependent manner, (P = 0.009 at 1 ,iM and P <0.0001 at 10 JiM). Treatment with 1 JIM genistein, another modulator of tyrosine kinases, had no effect on the ability of either taxol or cDDP to increase luciferase activity (data not shown). Thus, the signal transduction pathways leading to activation of the GADD153 promoter by cDDP and taxol differ at least with respect to the extent of involvement of a tyrphostin inhibitable kinase. Effect of tyrphostin B46 on the toxicity of cDDP and taxol In order to investigate the effect of GADD153 promoter activation on the toxicity of cDDP and taxol in the 2008 cells, we performed colony-forming assays. The cells were allowed to attach overnight, exposed to 1O JIM tyrphostin B46 for 1 h and then concurrently with cDDP (1 h) or taxol (24 h). As shown in Figure 6 , incubation with 10 JIM tyrphostin B46 decreased the IC50 of cisplatin 2.3-fold from 5.0 JIM cDDP to 2.2 jaM cDDP (P = 0.013, t-test). Since tyrphostin B46 is slightly toxic (1OJM is an IC5), one cannot determine whether the interaction with cDDP is additive, antagonistic or synergistic simply by subtraction. In order to determine the nature of this interaction, the toxicity of cDDP and tyrphostin B46 were investigated using median effect analysis (Chou and Talalay, 1986) . Median effect analysis is a mathematically formal method of determining synergy, additivity or antagonism. If the combination index for the two drugs is equal to 1, the effect is additive, if the index is above 1 the effect is antagonistic, and if the combination index is below 1 the effect is synergistic. As shown in Figure 7 , the majority of the combination index curve for cDDP and tyrphostin B46 falls below 1, indicating that the effect of the drugs is synergistic.
Since tyrphostin B46 decreased the activation of the GADD153 promoter after cDDP exposure and also increased cDDP cytotoxicity, we investigated the effect of tyrphostin B46 on the cytotoxicity of taxol, in which tyrphostin had no effect on the activation of the GADD153 promoter. As shown in Figure 
Discussion
The data presented in this report show that the activation of the GADD153 promoter can occur through at least two distinct pathways, here defined by cDDP and taxol. There are three major pieces of evidence to suggest that two pathways exist (1) the relationship between activation of the promoter and increase in endogenous GADD153 RNA is different for the two drugs; (2) the two drugs also differ in the relationship between cytotoxicity and change in endogenous GADD153 RNA levels; (3) the promoter activation pathways are differentially inhibitable by tyrphostin B46.
The magnitude of the activation of the GADD153 promoter corresponds closely to the change produced in endogenous mRNA level in response to activation of the taxol-inducible pathway (slope 1.1), but this relation is quite different for the pathway activated by cDDP (slope 29.5). Stated another way, for a given degree of activation of the transfected GADD153 promoter, cDDP produced a much greater increase in endogenous GADD153 mRNA than taxol. The ability of cDDP to activate the transfected GADD153 promoter is rather weak. Based on results obtained with the promoter construct used in this study, the effect of cDDP on endogenous GADD153 levels is likely to be mediated by elements other than those represented by the promoter elements present in pGADD-LUC. Alternative mechanisms such as stabilisation of the GADD153 message may also play an important role in increasing GADD153 mRNA levels in response to either drug. Jackman et al. (1994) have reported that DNA-damaging drugs will stabilise GADD153 RNA and increase mRNA half-life, yet agents that cause cell cycle arrest (such as serum starvation and prostaglandin A2) do not increase mRNA half-life. Our results are consistent with these findings. However, while we cannot exclude the possibility that increased mRNA stability accounts for the 26- fold difference between the increase in mRNA levels and promoter activity after cDDP-treatment, it seems more likely that the endogenous GADD153 gene contains promoter elements that are not contained in pGADD-LUC. It is probable that there are other response elements either 5', 3' or within the introns of GADD153. In the case of GADD45, another member of the DNA damage-inducible gene family, a p53-responsive element is known to lie within the third intron (Kastan et al., 1992; Hollander et al., 1993) .
The second piece of evidence indicating that cDDP and taxol activate GADD153 expression by different mechanisms comes from the difference in the magnitude of the increase in GADD153 mRNA produced by equitoxic exposures to the two drugs. We have shown that equitoxic schedules of exposure to the same drug produce equal increases in GADD153 mRNA (Gately et al., 1994) . However, equitoxic exposures to cDDP and taxol produced quite different changes in the GADD153 message. For example, at an exposure of twice the IC50 (10 JLM for cDDP, 10 nM for taxol), cDDP increased the GADD153 message levels by 10-fold whereas taxol increased the message level by only 2-fold. The (Gately et al., 1994) . As the degree of damage increases, the cell should increase the levels of protective genes (i.e. GADD153). If this increase is blocked (for example, by tyrphostin B46), the cell would be expected to be more sensitive to the injury. In the absence of agents that block GADD153 promoter activity, increases in GADD153 mRNA levels should still be a good marker of tumour injury.
Treatments that produce cellular injury activate a number of different pathways that may be involved in the cellular response to damage (Kramer et al., 1990; Bartlett et al., 1992; Devary et al., 1992 Devary et al., , 1993 Zhan et al., 1993) . However, what role each of these responses plays in cell survival is still unknown. Our conclusion that there exist multiple pathways that can influence GADD153 expression is consistent with the GADD153 promoter being a convergence point for several independent signal transduction pathways uniquely involved in the detection of different kinds of cellular injury. Abbreviations: cDDP, cisplatin; gadd, growth arrest and DNA damage; IC50, concentration required to inhibit colony formation by 50%; TPA, 12-0-tetradecanoylphorbol-1 3-acetate; C/EBP, CAAT/enhancer-binding protein: LAP, liver-enriched transcriptional activator protein. 
